BidaskClub upgraded shares of Geron (NASDAQ:GERN) from a strong sell rating to a sell rating in a report published on Thursday morning.

Several other brokerages have also recently issued reports on GERN. Needham & Company LLC restated a hold rating on shares of Geron in a report on Friday, November 3rd. Stifel Nicolaus restated a hold rating and issued a $2.50 target price on shares of Geron in a report on Friday, November 3rd. Finally, Zacks Investment Research cut shares of Geron from a buy rating to a hold rating in a report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $3.75.

Shares of Geron (GERN) traded up $0.10 during midday trading on Thursday, reaching $2.04. 2,408,000 shares of the company’s stock were exchanged, compared to its average volume of 1,400,733. Geron has a twelve month low of $1.74 and a twelve month high of $3.15. The company has a market capitalization of $324.83, a PE ratio of -11.33 and a beta of 2.59.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. Geron had a negative net margin of 2,992.67% and a negative return on equity of 25.14%. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.40 million. During the same quarter last year, the business earned ($0.02) earnings per share. The business’s revenue was down 96.8% on a year-over-year basis. sell-side analysts predict that Geron will post -0.17 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. IHT Wealth Management LLC bought a new position in shares of Geron in the second quarter worth approximately $122,000. Russell Investments Group Ltd. bought a new position in shares of Geron in the second quarter worth approximately $114,000. Parametric Portfolio Associates LLC lifted its stake in Geron by 59.4% in the second quarter. Parametric Portfolio Associates LLC now owns 47,976 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 17,877 shares during the period. Zacks Investment Management purchased a new stake in Geron in the second quarter worth $148,000. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in Geron by 1.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 58,056 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 1,000 shares during the period. Hedge funds and other institutional investors own 39.21% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/01/15/geron-gern-upgraded-to-sell-by-bidaskclub.html.

About Geron

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.